Martin-Loeches, Ignacio
Shorr, Andrew F.
Wunderink, Richard G.
Kollef, Marin H.
Timsit, Jean-François
Yu, Brian
Huntington, Jennifer A.
Jensen, Erin
Bruno, Christopher J.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
https://doi.org/10.1186/s13054-021-03694-3
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial
https://doi.org/10.1186/s13054-021-03773-5
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
https://doi.org/10.1186/s13613-022-01084-8
Funding for this research was provided by:
Merck Sharp and Dohme
Article History
Received: 13 June 2022
Accepted: 8 November 2022
First Online: 11 February 2023
Declarations
:
: The ASPECT-NP study was conducted in accordance with the principles of Good Clinical Practice (GCP) as set forth in the International Conference on Harmonisation guidelines on GCP (ICH E6) and was approved by the institutional review boards at each participating center and regulatory agencies at each participating country. Informed consent was received from all participants (or legally acceptable representatives).
: Not applicable.
: IM-L has received consulting fees and honoraria from MSD and Pfizer. AFS has received medical writing support, consulting fees, and honoraria from MSD; consulting fees from Pfizer and Shionogi; honoraria from Pfizer, Shionogi, and La Jolla. RGW is a consultant to, has received medical writing support from, and has participated in advisory committees for MSD; has received an investigator-initiated grant from Calcimedica; has participated in advisory committees for Shionogi and La Jolla; has received honoraria from BioMerieux for industry workshops at ATS, APSR, and SCCM; and has participated in the Clinical Evaluation Committee for Pfizer. MHK is supported by Barnes-Jewish Hospital Foundation and has received consulting fees and honoraria from MSD, Pfizer, and Shionogi. J-FT participated on an advisory board for MSD, Pfizer, and Shionogi on treatment of HAP/VAP; has received research grants, consulting fees, honoraria, and travel support from MSD; was past chairman of the ESCMID Study Group for Infections in Critically Ill Patients—ESGCIP; and is the principal investigator of BICCS (national research program (RCT BICCS PHRC 18-0316) on the benefit of Continuous infusion and combination therapy on the treatment of severe Gram-negative infections, including pneumonia. JAH, EJ, and CJB, and BY are current or former employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and/or hold stock options in Merck & Co., Inc., Rahway, NJ USA.